RT Journal Article
SR Electronic
T1 Technology transfer of a dried blood virus neutralization assay to a GAVI-eligible country
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.23.24310857
DO 10.1101/2024.07.23.24310857
A1 Obodai, Evangeline
A1 Terstappen, Jonne
A1 Mensah, Jude Y.
A1 Versnel, Anouk
A1 Antwi, Comfort N.
A1 Bont, Louis J.
A1 Cianci, Daniela
A1 Delemarre, Eveline M.
A1 Odoom, John K.
A1 van de Ven, Peter M.
A1 Mazur, Natalie I.
YR 2024
UL http://medrxiv.org/content/early/2024/07/24/2024.07.23.24310857.abstract
AB Background Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income countries face barriers to participate, including lack of financial and human capacity and lack of research environment. Respiratory syncytial virus (RSV) vaccine development is also led by HICs, preventing global vaccine access while LMICs carry the burden of life-threatening disease. This study aims to transfer an RSV neutralization assay, which uses live cells and virus with inherent high variation, to a GAVI-eligible country.Methods Using a train-the-trainer approach, a Ghanaian researcher was trained in the Netherlands on the dried blood-based RSV neutralization assay. Subsequently, a Dutch researcher visited Ghana to support the process of adapting the technique to the Ghanaian setting. In a previously validated RSV neutralization assay on dried blood, Hep-2 cells were infected with a serial dilution of sample-virus mixture to determine the half-maximal inhibitory concentration. Fifty-one dried blood and serum samples were tested in parallel in both countries to assess concordance.Results Training and technology transfer was deemed successful, which was defined as neutralization measurements by the Ghana team and high concordance (Lin’s concordance correlation coefficient (CCC) > 0.8). Neutralizing capacity measured in identical samples in Ghana and the Netherlands correlated highly (Lin’s CCC = 0.87; Spearman rho = 0.89) but was systematically lower in Ghana than the Netherlands.Conclusion We show successful strengthening of the laboratory research capacity in a GAVI-eligible country. Reliable measurement of RSV neutralizing antibodies in a GAVI-eligible country and the use of dried blood can contribute to inclusion of LMICs in RSV vaccine development and access.Funding NoneWhat is already known?The global health research divide is evident in respiratory syncytial virus (RSV) vaccine development, where vaccines are developed and available in high-income countries (HICs), despite low- and middle-income countries (LMICs) bearing the majority of the disease burden. Representative trials and research capacity strengthening in LMICs are needed to ensure global vaccine access and equity.What this study adds?In this newly established partnership, we used a train-the-trainer approach to transfer a low-tech dried blood live-virus neutralization assay from the Netherlands to Ghana, a GAVI-eligible country. A sample panel measured in parallel in both countries showed high concordance and correlation despite the difficulties of running a bioassay with inherently high variability while using distinct materials.How this study might affect research, practice, or policy?The Ghana laboratory will leverage the established RSV neutralization assay to serve as a research hub in Africa supporting other LMICs to perform clinical sample analysis and management of clinical trial samples, ultimately reducing barriers to clinical trials and vaccine access, thereby advancing the sustainable development goals.Competing Interest StatementEO, JT, JYM, CNA and NIM have received support for attending meetings and/or travel from the ResViNET Foundation. UMC Utrecht has received grants from AbbVie, AstraZeneca, The Bill & Melinda Gates Foundation, The Gates Medical Research Institute, GSK, Janssen, the Lung Foundation Netherlands, MedImmune, MeMed, Merck, Novavax, Pfizer, and Sanofi; LB and NIM have received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Ablynx, Astrazeneca, Bavaria Nordic, GSK, Janssen, MabXience, MedImmune, MEDtalks, Merck, Moderna, Novavax, Pfizer, Sanofi and Virology Education. LB is founding chairman of the ReSViNET Foundation. All other authors have nothing to declare.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University Medical Center Utrecht gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesOn reasonable request to the corresponding authors, the data can be shared with publication.